Published in J Pathol on March 01, 1998
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Pulmonary preinvasive neoplasia. J Clin Pathol (2001) 2.02
Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features. Br J Cancer (2000) 0.89
Tobacco smoking as a risk factor of bronchioloalveolar carcinoma of the lung: pooled analysis of seven case-control studies in the International Lung Cancer Consortium (ILCCO). Cancer Causes Control (2010) 0.88
Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. Lung Cancer (2006) 0.87
Loss of FHIT protein expression correlates with disease progression and poor differentiation in gastric cancer. J Cancer Res Clin Oncol (2003) 0.85
Frequent allelic deletion at the FHIT locus associated with p53 overexpression in squamous cell carcinoma subtype of Taiwanese non-small-cell lung cancers. Br J Cancer (2004) 0.81
NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma. Cancer Med (2016) 0.75
Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst (1988) 5.42
A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell (1992) 4.96
Hirschsprung disease, associated syndromes and genetics: a review. J Med Genet (2007) 4.13
Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science (1994) 4.07
Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet (1992) 3.77
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch (2008) 2.78
A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. EMBO J (1995) 2.52
Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling. Ann Oncol (2009) 2.13
The receptor of the type I interferon family. Curr Top Microbiol Immunol (2007) 1.94
Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol (2004) 1.88
AKT1(E17K) in human solid tumours. Oncogene (2008) 1.87
Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res (1997) 1.85
Int-6, a highly conserved, widely expressed gene, is mutated by mouse mammary tumor virus in mammary preneoplasia. J Virol (1995) 1.79
Interferon-alpha-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase. J Biol Chem (1996) 1.78
Causative and susceptibility genes for Alzheimer's disease: a review. Brain Res Bull (2003) 1.76
Altered expression of NM23, a gene associated with low tumor metastatic potential, during adenovirus 2 Ela inhibition of experimental metastasis. Cancer Res (1988) 1.75
Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression. J Pathol (1994) 1.65
Intrahepatic metastatic nodules of hepatocellular carcinoma detected at lipiodol-CT: imaging-pathologic correlation. Abdom Imaging (1997) 1.63
Surgery plus adjuvant chemotherapy for T1-3N0M0 small-cell lung cancer. Rationale for current approach. Am J Clin Oncol (1991) 1.56
Results and prognostic factors of surgery in the management of non-small cell lung cancer with solitary brain metastasis. Cancer (1991) 1.56
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res (1998) 1.54
Pulmonary lipid peroxidation in cigarette smokers and lung cancer patients. Chest (1990) 1.52
Isolation and characterization of a new mutant human cell line unresponsive to alpha and beta interferons. Mol Cell Biol (1991) 1.52
Thymic carcinoma: a report of 13 cases. Eur J Surg Oncol (2001) 1.52
The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene (1999) 1.44
Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-alpha/beta and for signal transduction. J Biol Chem (1995) 1.41
Most peripheral, node-negative, non-small-cell lung cancers have low proliferative rates and no intratumoral and peritumoral blood and lymphatic vessel invasion. Rationale for treatment with wedge resection alone. J Thorac Cardiovasc Surg (1992) 1.41
Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst (1997) 1.41
Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. J Pathol (1996) 1.40
Quality control for biomarker determination in oncology: the experience of the Italian Network for Quality Assessment of Tumor Biomarkers (INQAT). Int J Biol Markers (2002) 1.40
Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol (1995) 1.40
The amino-terminal region of Tyk2 sustains the level of interferon alpha receptor 1, a component of the interferon alpha/beta receptor. Proc Natl Acad Sci U S A (1997) 1.40
Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res (1997) 1.39
The NM23 gene maps to human chromosome band 17q22 and shows a restriction fragment length polymorphism with BglII. Genes Chromosomes Cancer (1992) 1.34
Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. J Med Genet (2004) 1.33
Small cell lung cancer. Ann Oncol (2006) 1.30
A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-alpha signaling. Proc Natl Acad Sci U S A (2000) 1.27
Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer (1995) 1.27
Amplification and excision of integrated polyoma DNA sequences require a functional origin of replication. Cell (1984) 1.26
Reduced expression of INT-6/eIF3-p48 in human tumors. Int J Oncol (2001) 1.26
Regulation of polyomavirus late promoter activity by viral early proteins. J Virol (1986) 1.26
p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer (1997) 1.21
Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer (1995) 1.19
A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer (2002) 1.19
Specific contribution of Tyk2 JH regions to the binding and the expression of the interferon alpha/beta receptor component IFNAR1. J Biol Chem (1998) 1.19
A pilot study of the role of TC-99 radionuclide in localization of pulmonary nodular lesions for thoracoscopic resection. Eur J Cardiothorac Surg (2000) 1.18
Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma. Cancer (1991) 1.15
Role of electrothrombosis in aneurysm treatment with Guglielmi detachable coils: an in vitro scanning electron microscopic study. AJNR Am J Neuroradiol (2001) 1.15
The chromosome location of the human homolog of the mouse mammary tumor-associated gene INT6 and its status in human breast carcinomas. Genomics (1997) 1.15
The Janus kinase family of protein tyrosine kinases and their role in signaling. Cell Mol Life Sci (1999) 1.15
Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res (1996) 1.14
Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas. Br J Cancer (1996) 1.12
Interferon alpha inhibits a Src-mediated pathway necessary for Shigella-induced cytoskeletal rearrangements in epithelial cells. J Cell Biol (1998) 1.12
Double heterozygosity for a RET substitution interfering with splicing and an EDNRB missense mutation in Hirschsprung disease. Am J Hum Genet (1999) 1.12
Gastropleural fistula as complication of postpneumonectomy empyema. J Cardiovasc Surg (Torino) (2000) 1.11
Resection of single brain metastasis in non-small-cell lung cancer: prognostic factors. J Thorac Cardiovasc Surg (1996) 1.10
Diploid/triploid mosaicism: further delineation of the phenotype. Am J Med Genet (1994) 1.08
Ghrelin tissue distribution: comparison between gene and protein expression. J Endocrinol Invest (2006) 1.08
Negative regulation of type I interferon signaling: facts and mechanisms. Cell Mol Biol (Noisy-le-grand) (2006) 1.07
Surgical approaches to membranous tracheal wall lacerations. J Thorac Cardiovasc Surg (2000) 1.07
Hemodynamic and metabolic impairment in acute pancreatitis. World J Surg (1981) 1.07
p53 mutations and histological type of invasive breast carcinoma. Cancer Res (1993) 1.06
Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br J Cancer (1997) 1.06
Endotoxemia, encephalopathy, and mortality in cirrhotic patients. Am J Gastroenterol (1987) 1.06
p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene (1996) 1.05
p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res (1993) 1.05